SEC
NXTM

Seven Eight Capital’s NxStage Medical Inc. NXTM Stock Holding History

Seven Eight Capital’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,000
Closed -$469K – 632
2017
Q3 		$469K Buy
+17,000
New +$453K 0.06% 351

Other funds holding NXTM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seven Eight Capital's NXTM Position: Q4 2017 in Review

Seven Eight Capital sold out of NxStage Medical Inc. (NXTM) in Q4 2017, closing a stake of 17,000 shares — an estimated $469K sold.

Seven Eight Capital first reported a position in NXTM in Q3 2017 and held it in 1 quarter. The position peaked at $469K in Q3 2017. 178 funds tracked by Wall St. Rank hold NXTM as of Q4 2017.

  • Seven Eight Capital reported no remaining NxStage Medical Inc. position as of Q4 2017 after selling out during the quarter.
  • Seven Eight Capital sold 17,000 NxStage Medical Inc. shares in Q4 2017, an estimated $469K.
  • Seven Eight Capital first reported a position in NxStage Medical Inc. in Q3 2017 and held it in 1 quarter.
  • Seven Eight Capital's NxStage Medical Inc. position peaked at $469K in Q3 2017.
  • 178 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q4 2017.

Based on Seven Eight Capital's 13F filing for Q4 2017, filed 12 Feb 2018.